What is the recommended treatment approach for mesial temporal sclerosis (medial temporal sclerosis) causing drug‑resistant temporal lobe epilepsy?

Treatment of Medial Temporal Sclerosis with Drug-Resistant Epilepsy

Patients with medial temporal sclerosis causing drug-resistant temporal lobe epilepsy should be referred immediately for surgical evaluation after failure of two appropriately chosen antiseizure medications, as surgical resection offers 60-80% seizure freedom rates compared to essentially 0% with continued medical management alone. 1

Defining Drug-Resistance and Timing of Referral

Drug-resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen antiseizure medication schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. 1 Once this threshold is met, referral should occur immediately without delay - the evidence is unequivocal that additional medication trials yield only 2-4% chance of seizure freedom. 1

Critical Point on Timing

Do not delay surgical referral for any of the following reasons: 1

• Waiting to try additional non-medication therapies
• Patient reluctance to surgery (refer for evaluation/counseling anyway)
• Expectation that surgery will only be "palliative"
• Prior failed surgical resection
• Medication failure due to side effects rather than lack of efficacy
• Patient age up to 70 years

The 2022 ILAE expert consensus is explicit: referral should be offered to every patient with drug-resistant epilepsy up to 70 years of age, regardless of epilepsy duration, sex, socioeconomic status, seizure type, comorbidities, or localization. 1

Surgical Treatment Options

Gold Standard: Anterior Temporal Lobectomy (ATL)

ATL remains the gold-standard treatment with proven efficacy in two Class I trials demonstrating 60-80% seizure freedom rates at 2-year follow-up. 2 Recent data confirms these outcomes persist long-term, with one 2024 study showing 80.3% Engel I outcomes at median 5.7-year follow-up in patients ≥50 years. 3

Selective Amygdalohippocampectomy (SAH)

SAH with relative sparing of lateral temporal neocortex demonstrates 78.2% seizure freedom rates while providing superior neuropsychological outcomes, particularly for visual encoding, verbal and visual short-term memory, and visual working memory compared to standard temporal lobectomy. 4 This approach should be strongly considered when memory preservation is a priority.

Minimally Invasive Option: MRgLITT

Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) has emerged as a less invasive alternative with 44-78% seizure freedom rates at 1-year follow-up (meta-analyses report 55-58%). 2 The 2022 ASSFN position statement endorses MRgLITT as an appropriate option for mesial temporal epilepsy, noting:

• Shorter hospital stay (1 night vs 3-4 nights for open surgery)
• Less surgical and neurological morbidity
• Rapid return to normal activity
• Real-time MRI monitoring to minimize collateral damage 2

Important caveat: MRgLITT seizure freedom rates are slightly lower than open ATL (similar to open SAH outcomes), but many patients prefer this trade-off for reduced invasiveness. 2

Algorithmic Approach to Surgical Decision-Making

1. Confirm drug-resistance: Two failed appropriate ASM trials

2. Immediate referral to epilepsy surgery center for comprehensive evaluation including:

   • Video-EEG monitoring
   • High-resolution epilepsy-protocol MRI
   • Neuropsychological testing
   • Functional imaging if needed

3. Surgical candidacy determination:

   • Unilateral mesial temporal onset confirmed: Proceed to surgery discussion
   • Bilateral findings on standard evaluation: Consider chronic ambulatory intracranial EEG (e.g., RNS system) - 38% of presumed bilateral cases show unilateral onsets on long-term monitoring and achieve 100% seizure freedom after resection 5

4. Surgical approach selection:

   • Standard ATL: Best seizure freedom rates (60-80%)
   • SAH: Consider when memory preservation is critical; slightly lower seizure freedom but superior cognitive outcomes 4
   • MRgLITT: Consider when patient prefers minimally invasive approach or refuses open surgery; accept 55-58% seizure freedom rate 2

Critical Outcomes Data

Mortality benefit: Surgical treatment is the only intervention proven to improve survival and reverse excess mortality attributed to drug-resistant epilepsy. 1 Importantly, mortality normalization occurs even without complete seizure freedom, as long as there is reduction in seizures with impaired awareness. 2

Quality of life: Improves in approximately 90-95% of patients regardless of surgical approach (SAH vs STL). 4

Age considerations: Surgery is equally effective and safe in patients ≥50 years compared to younger patients, with 80.3% achieving Engel I outcomes and comparable complication rates (3.3% vs 2.7%). 3 Consider referral even in patients >70 years without surgical contraindications. 1

Common Pitfalls to Avoid

• Delaying referral while trying multiple additional ASMs: After two failures, likelihood of medication success is <4% 1
• Assuming bilateral temporal findings preclude surgery: Long-term ambulatory ICEEG can identify lateralization in many cases 5
• Withholding referral due to psychiatric comorbidity: Refer if patient is cooperative with management 1
• Age discrimination: Outcomes are equivalent in older patients 3

Only contraindication to referral: Active substance abuse with non-cooperation with management 1